This study was limited to triple aPL-positive (anti- β2GPI, aCL and LA positive) thrombotic APS patients, a high-risk group in which the same authors previously reported recurrent thrombosis in 30% of patients on standard intensity warfarin [22], and included patients with arterial thrombosis in addition to venous thrombosis,. This evidence concerns the gene ACLY and Venous thrombosis.